ATE189230T1 - T-zell rezeptorpeptide als therapeutika für immun-verwandte krankheiten - Google Patents

T-zell rezeptorpeptide als therapeutika für immun-verwandte krankheiten

Info

Publication number
ATE189230T1
ATE189230T1 AT92912864T AT92912864T ATE189230T1 AT E189230 T1 ATE189230 T1 AT E189230T1 AT 92912864 T AT92912864 T AT 92912864T AT 92912864 T AT92912864 T AT 92912864T AT E189230 T1 ATE189230 T1 AT E189230T1
Authority
AT
Austria
Prior art keywords
immune
cell receptor
tcr
therapeutics
related diseases
Prior art date
Application number
AT92912864T
Other languages
English (en)
Inventor
Arthur Allen Vandenbark
Original Assignee
Connetics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Connetics Corp filed Critical Connetics Corp
Application granted granted Critical
Publication of ATE189230T1 publication Critical patent/ATE189230T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT92912864T 1991-05-31 1992-06-01 T-zell rezeptorpeptide als therapeutika für immun-verwandte krankheiten ATE189230T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US70802291A 1991-05-31 1991-05-31
US73561291A 1991-07-16 1991-07-16
PCT/US1992/004492 WO1992021367A1 (en) 1991-05-31 1992-06-01 T cell receptor peptides as therapeutics for immune-related disease

Publications (1)

Publication Number Publication Date
ATE189230T1 true ATE189230T1 (de) 2000-02-15

Family

ID=27108005

Family Applications (1)

Application Number Title Priority Date Filing Date
AT92912864T ATE189230T1 (de) 1991-05-31 1992-06-01 T-zell rezeptorpeptide als therapeutika für immun-verwandte krankheiten

Country Status (11)

Country Link
EP (1) EP0587735B1 (de)
JP (1) JPH07502977A (de)
AT (1) ATE189230T1 (de)
AU (1) AU674494B2 (de)
CA (1) CA2110055C (de)
DE (1) DE69230612T2 (de)
DK (1) DK0587735T3 (de)
ES (1) ES2144418T3 (de)
GR (1) GR3033318T3 (de)
NO (1) NO934320L (de)
WO (1) WO1992021367A1 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5667967A (en) * 1990-05-01 1997-09-16 The Board Of Trustees Of The Leland Stanford Junior University T-cell receptor varible transcripts as disease related markers
US5776459A (en) * 1989-07-19 1998-07-07 Connetics Corporation TCR V beta 5 peptides
ATE244299T1 (de) * 1992-12-18 2003-07-15 Molecular Rx Inc Test und behandlung von demyelinierenden krankheiten wie multiple sklerosis
GB9308581D0 (en) * 1993-04-26 1993-06-09 Univ Manitoba A method for induction of antigen-specific suppression of immune-response
AU6376194A (en) * 1993-05-14 1994-12-12 Dr. L. Willems-Instituut Human t cell monoclone, process for its production and its use, diagnostic of infectious diseases, autoimmune diseases, t-cell mediated allergies and cancer
EP0720622A1 (de) * 1993-09-22 1996-07-10 The Board Of Trustees Of The Leland Stanford Junior University Wechselwirkung zwischen t-zellrezeptoren und antigen in autoimmunkrankheiten
US5552300A (en) * 1994-01-13 1996-09-03 T Cell Sciences, Inc. T cell antigen receptor V region proteins and methods of preparation thereof
US6329499B1 (en) * 1994-11-18 2001-12-11 Neurocrine Biosciences, Inc. Methods for treatment of multiple sclerosis using peptide analogues of human myelin basic protein
US6251396B1 (en) 1994-11-18 2001-06-26 Neurocrine Biosciences, Inc. Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein
EP1172376A1 (de) 1994-11-18 2002-01-16 Neurocrine Biosciences, Inc. Peptidanaloge des menschlichen, basischen myelinproteins mit substitution an position 91 zur behandlung der multiplen sklerose
US6379670B1 (en) 1994-11-18 2002-04-30 Neurocrine Biosciences, Inc. Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein
WO1996028470A2 (en) * 1995-03-09 1996-09-19 Neurocrine Biosciences, Inc. Peptide analogues of human myelin basic protein useful in treating multiple sclerosis
IL113159A0 (en) * 1995-03-28 1995-06-29 Yeda Res & Dev Synthetic peptides and pharmaceutical compositions comprising them
AU2651997A (en) * 1996-05-10 1997-12-05 Kirin Beer Kabushiki Kaisha T-cell receptor alpha-chain constant-region peptides, processes for producing the peptides, and use thereof
EP2322216A1 (de) 1997-03-21 2011-05-18 Chugai Seiyaku Kabushiki Kaisha Präventives oder therapeutisches Mittel mit einem IL-6-Antagonisten als Wirkstoff für durch sensibilisierte T-Zellen vermittelte Erkrankungen
EP2050814A1 (de) 2007-10-17 2009-04-22 Txcell Zusammensetzungen zur Behandlung von Multipler Sklerose
EP3122768A2 (de) * 2014-03-27 2017-02-01 Yeda Research and Development Co. Ltd. T-zell-rezeptor-cdr3-peptide und -antikörper

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4886743A (en) * 1985-04-24 1989-12-12 California Institute Of Technology Diagnostic reagents based on unique sequences within the variable region of the T cell receptor and uses thereof
ES2062519T5 (es) * 1989-03-21 2003-07-16 Immune Response Corp Inc Vacunacion y metodos contra enfermedades originadas a partir de respuestas patogenicas mediante poblaciones especificas de linfocitos t.
IL95125A (en) * 1989-07-19 1995-07-31 Vandenbark Arthur Allen T cell peptides receive a method for their selection and preparation, and pharmaceutical preparations containing them
JPH06507384A (ja) * 1991-01-22 1994-08-25 ザ　イミューン　レスポンス　コーポレイション 特定のｔ細胞群による病理的応答により生じる疾患に対するワクチン投与および方法

Also Published As

Publication number Publication date
ES2144418T3 (es) 2000-06-16
GR3033318T3 (en) 2000-09-29
DE69230612D1 (de) 2000-03-02
NO934320L (no) 1994-01-27
CA2110055C (en) 2002-08-20
EP0587735A1 (de) 1994-03-23
JPH07502977A (ja) 1995-03-30
EP0587735A4 (de) 1995-05-03
DE69230612T2 (de) 2000-06-21
AU674494B2 (en) 1997-01-02
CA2110055A1 (en) 1992-12-10
DK0587735T3 (da) 2000-09-11
WO1992021367A1 (en) 1992-12-10
EP0587735B1 (de) 2000-01-26
NO934320D0 (no) 1993-11-29
AU2147292A (en) 1993-01-08

Similar Documents

Publication Publication Date Title
DK0552142T3 (da) T-cellereceptorpeptider og terapeutika til autoimmune og maligne sygdomme
ATE189230T1 (de) T-zell rezeptorpeptide als therapeutika für immun-verwandte krankheiten
Dales et al. Infection with vaccinia favors the selection of hybridomas synthesizing autoantibodies against intermediate filaments, one of them cross-reacting with the virus hemagglutinin.
IL122211A0 (en) Modified/chimeric superantigens and their use
US4652629A (en) Synthetic peptide-based anti-rabies compositions and methods
Chess et al. Leukocyte inhibitory factor (LIF): production by purified human T and B lymphocytes
Quaranta et al. The free and the β2-microglobulin-associated heavy chains of HLA-A, B alloantigens share the antigenic determinant recognized by the monoclonal antibody Q1/28
Antón et al. A transmissible gastroenteritis coronavirus nucleoprotein epitope elicits T helper cells that collaborate in the in vitro antibody synthesis to the three major structural viral proteins
ATE122894T1 (de) Verwendung und zusammensetzung zur verbesserung des ''targeting'' von antikörpern, antikörperteilen, sowie konjugate derselben.
JPS6327498A (ja) Ｈｔｌｖ−ｉｉｉ／ｌａｖウイルス関連ペプチド
Thomas et al. Heterogeneity and specificity of human anti-insulin antibodies determined by isoelectric focusing.
US6682896B1 (en) Peptides representing epitopic sites on r-IFN-β, antibodies thereto and uses thereof
JP2717319B2 (ja) Ｒ―ｉｆｎ―ベータエピトープ部位を代表するペプチド、それに対する抗体、およびその用途
MATSUDA et al. Protection from pseudorabies virus challenge in mice by a combination of purified gII, gIII and gVI antigens
KR930703445A (ko) 톡소플라스마 곤디(toxoplasma gondii)의 단백질 항원의 클로닝 및 발현
KR940005665A (ko) 분리된 폴리펩티드, 이를 암호하는 핵산 분자, 상기 폴리펩티드를 포함하는 조성물 및 이를 사용하는 방법
Davignon et al. Clonal analysis of H-2Kb+ TNP recognition by T cells with the use of H-2Kbm mutants and H-2Kb-specific monoclonal antibodies.
Fischer et al. Synthetic peptide antigens of tetanus toxin
Kwok et al. Human interferon-gamma has three domains associated with its antiviral function: a neutralizing epitope typing scheme for human interferon-gamma
US5066593A (en) Synthetic peptide-based anti-rabies compositions and methods
Yu et al. Induction of High Levels of Epitope‐Specific Antibodies by Epitope/Peptide Candidate Vaccines against Human Immunodeficiency Virus Type‐1 (HIV‐1)
PyhäLä Neutralizing antibodies against human leukocyte, lymphoblastoid and fibroblast interferons elicited by immunization with human leukocyte interferon
IL150045A0 (en) Compositions and methods for detecting stress-inducible proteins
Wexler et al. Studies on the induction and expression of T-cell-mediated immunity: XIII. Membrane-associated antigens of cytotoxic T lymphocytes involved in cytotoxicity
Kelner et al. A single amino acid substitution in a cytochrome c T cell stimulatory peptide changes the MHC restriction element from one isotype (I-Ak) to another (I-Ek)

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EEIH Change in the person of patent owner
REN Ceased due to non-payment of the annual fee